Crispr Therapeutics Ag Stock Number Of Shares Shorted
| 1CG Stock | 40.80 0.00 0.00% |
CRISPR Therapeutics AG fundamentals help investors to digest information that contributes to CRISPR Therapeutics' financial success or failures. It also enables traders to predict the movement of CRISPR Stock. The fundamental analysis module provides a way to measure CRISPR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CRISPR Therapeutics stock.
CRISPR |
CRISPR Therapeutics AG Company Number Of Shares Shorted Analysis
CRISPR Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, CRISPR Therapeutics AG has 0.0 of outstending shares currently sold short by investors. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Number Of Shares Shorted (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
CRISPR Fundamentals
| Current Valuation | 2.16 B | |||
| Price To Book | 6.67 X | |||
| Price To Sales | 1,731 X | |||
| Revenue | 436 K | |||
| EBITDA | (648.99 M) | |||
| Net Income | (650.17 M) | |||
| Cash Flow From Operations | (495.74 M) | |||
| Market Capitalization | 4.99 B | |||
| Total Asset | 2.24 B | |||
| Net Asset | 2.24 B |
About CRISPR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.